Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.
The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.
Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center will offer further insights on narcolepsy at the upcoming International Congress on the Future of Neurology, September 27-28, 2019 in New York City.
As home-monitoring devices become more available, accessible, and useful, they are increasing becoming helpful in neurological decision-making. More in this video.
College athletes may be sabotaging their careers—as well as their performance—when they sacrifice sleep for sports, studying, and socializing.
Obstructive sleep apnea may affect the accumulation of tau in the brain.
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
EEG and brain MRI findings are normal—what do you suspect?
It turns out that sleep deprivation has an effect not only on the traditional concept of “beauty,” but also on whether a person is perceived as being socially desirable.